Finasteride, a common hormone-blocking drug, reduces men’s risk of getting prostate cancer without increasing their risk of dying from the disease, according to long-term follow-up data.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
